Teva Pharmaceutical Industries (TEVA)
Teva Pharmaceutical Industries on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
29.8M
Short interest
settlement 2026-09-30
5.4
Days to cover
-22.0 days vs prior
36.2%
Short share of volume
2026-10-09
12,764
Fails to deliver
settlement 2026-09-14
Wed 4 Nov
Next earnings
estimated date
-$17.0M
Insider flow, 90 days
0 buys, 11 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in TEVA is 29,848,805 shares, down 7,765,448 shares over the last month. Over the last 48 readings it ranged from 15,797,023 shares (15 January 2025) to 55,193,262 shares (15 September 2025). At the reported average volume of 5.5M shares a day that is 5.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/teva" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 29,848,805 | -5.2% | 5,530,389 | 5.40 |
| 2026-09-15 | 31,478,314 | +11467.5% | 1,150,992 | 27.35 |
| 2026-08-31 | 37,614,253 | +5.5% | 4,877,029 | 7.71 |
| 2026-08-14 | 35,670,864 | +3.9% | 5,379,181 | 6.63 |
| 2026-07-31 | 34,320,980 | +4.8% | 5,976,563 | 5.74 |
| 2026-07-15 | 32,741,011 | +2.2% | 5,031,824 | 6.51 |
| 2026-06-30 | 32,029,657 | -4.0% | 6,283,326 | 5.10 |
| 2026-06-15 | 33,346,891 | -1.5% | 6,149,216 | 5.42 |
| 2026-05-29 | 33,869,008 | +27.1% | 5,646,510 | 6.00 |
| 2026-05-15 | 26,651,458 | -14.4% | 6,682,365 | 3.99 |
| 2026-04-30 | 31,140,457 | +4.7% | 7,780,794 | 4.00 |
| 2026-04-15 | 29,736,398 | +10.0% | 4,191,168 | 7.10 |
| 2026-03-31 | 27,042,748 | -28.1% | 7,063,669 | 3.83 |
| 2026-03-13 | 37,623,025 | +15.7% | 8,864,221 | 4.24 |
| 2026-02-27 | 32,527,649 | -11.2% | 6,457,336 | 5.04 |
| 2026-02-13 | 36,644,722 | -3.5% | 10,104,694 | 3.63 |
| 2026-01-30 | 37,953,087 | +15.1% | 10,894,419 | 3.48 |
| 2026-01-15 | 32,969,413 | +0.3% | 11,356,232 | 2.90 |
| 2025-12-31 | 32,862,069 | -26.9% | 6,967,049 | 4.72 |
| 2025-12-15 | 44,936,239 | -1.5% | 10,908,959 | 4.12 |
| 2025-11-28 | 45,620,941 | -1.8% | 10,577,486 | 4.31 |
| 2025-11-14 | 46,443,487 | -7.8% | 18,429,877 | 2.52 |
| 2025-10-31 | 50,392,932 | +6.6% | 8,663,070 | 5.82 |
| 2025-10-15 | 47,284,149 | -5.2% | 8,949,285 | 5.28 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of TEVA volume is 36.2%, down 12.3 points over the last five sessions. Over the last 30 readings it ranged from 23.1% (21 September 2026) to 75.6% (1 October 2026). The latest reading is 7.2 points below the 30-session average of 43.4%, on 7.8M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 2.8M | 7.8M | 36.2% | 6,828 |
| 2026-10-08 | 1.4M | 3.2M | 42.9% | 0 |
| 2026-10-07 | 670K | 1.2M | 56.9% | 512 |
| 2026-10-06 | 1.2M | 3.0M | 40.1% | 101 |
| 2026-10-05 | 517K | 1.6M | 33.1% | 2,528 |
| 2026-10-02 | 892K | 1.8M | 48.5% | 712 |
| 2026-10-01 | 2.3M | 3.0M | 75.6% | 14,394 |
| 2026-09-30 | 1.2M | 2.5M | 49.3% | 5,920 |
| 2026-09-29 | 1.3M | 3.7M | 35.8% | 13,561 |
| 2026-09-28 | 820K | 1.7M | 47.4% | 4,052 |
| 2026-09-25 | 550K | 1.4M | 39.0% | 617 |
| 2026-09-24 | 966K | 3.9M | 24.6% | 3,422 |
| 2026-09-23 | 912K | 2.4M | 38.0% | 400 |
| 2026-09-22 | 678K | 2.1M | 32.9% | 3,739 |
| 2026-09-21 | 663K | 2.9M | 23.1% | 1,340 |
| 2026-09-18 | 919K | 1.6M | 56.9% | 2,910 |
| 2026-09-17 | 937K | 2.3M | 41.5% | 4 |
| 2026-09-16 | 1.1M | 2.3M | 48.5% | 3,300 |
| 2026-09-15 | 1.5M | 2.6M | 58.1% | 5,765 |
| 2026-09-14 | 468K | 1.4M | 32.5% | 3,264 |
| 2026-09-11 | 852K | 1.2M | 69.3% | 0 |
| 2026-09-10 | 685K | 1.6M | 43.9% | 190 |
| 2026-09-09 | 658K | 1.4M | 46.2% | 687 |
| 2026-09-08 | 932K | 1.8M | 51.4% | 1,751 |
| 2026-09-04 | 337K | 1.0M | 32.3% | 1,523 |
| 2026-09-03 | 682K | 1.3M | 51.0% | 3,805 |
| 2026-09-02 | 1.5M | 3.3M | 45.3% | 1,259 |
| 2026-09-01 | 416K | 1.1M | 36.8% | 3,383 |
| 2026-08-31 | 509K | 1.7M | 29.7% | 6,147 |
| 2026-08-28 | 439K | 1.3M | 35.0% | 2,822 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in TEVA is 12,764 shares, up 12,400 shares over the last settlement date. Over the last 30 readings it ranged from 15 shares (17 July 2026) to 215,215 shares (9 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 12,764 | $37.09 | $473K |
| 2026-09-09 | 364 | $36.76 | $13K |
| 2026-09-04 | 66 | $36.62 | $2K |
| 2026-09-02 | 144 | $36.19 | $5K |
| 2026-09-01 | 1,611 | $36.05 | $58K |
| 2026-08-26 | 7,094 | $38.10 | $270K |
| 2026-08-24 | 142,931 | $37.34 | $5.3M |
| 2026-08-21 | 8,026 | $36.81 | $295K |
| 2026-08-19 | 156 | $36.58 | $6K |
| 2026-08-18 | 780 | $36.46 | $28K |
| 2026-08-17 | 96 | $36.77 | $4K |
| 2026-08-12 | 907 | $36.48 | $33K |
| 2026-08-04 | 177 | $34.46 | $6K |
| 2026-08-03 | 588 | $35.01 | $21K |
| 2026-07-23 | 26,824 | $30.15 | $809K |
| 2026-07-17 | 15 | $32.22 | $483 |
| 2026-07-09 | 215,215 | $33.24 | $7.2M |
| 2026-07-07 | 44 | $35.29 | $2K |
| 2026-06-30 | 3,823 | $33.31 | $127K |
| 2026-06-25 | 391 | $34.22 | $13K |
| 2026-06-23 | 4,960 | $32.20 | $160K |
| 2026-06-22 | 131 | $31.48 | $4K |
| 2026-06-15 | 1,420 | $34.63 | $49K |
| 2026-06-10 | 255 | $34.45 | $9K |
| 2026-06-05 | 200 | $34.43 | $7K |
| 2026-05-28 | 581 | $34.56 | $20K |
| 2026-05-27 | 5,613 | $34.61 | $194K |
| 2026-05-19 | 30,057 | $34.03 | $1.0M |
| 2026-05-13 | 100,000 | $35.81 | $3.6M |
| 2026-04-24 | 6,722 | $31.21 | $210K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at TEVA reported 11 open-market sells worth $17.0M in the last 90 days and no open-market buys. Latest filing: Savage Brian (Interim Chief Legal Officer) on 2026-09-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Savage Brian | Interim Chief Legal Officer | Sell | 314 | $38.70 | $12K | 9K |
| 2026-09-18 | Savage Brian | Interim Chief Legal Officer | Sell | 3K | $39.15 | $99K | 9K |
| 2026-09-18 | Savage Brian | Interim Chief Legal Officer | Sell | 5K | $38.69 | $174K | 11K |
| 2026-09-18 | Savage Brian | Interim Chief Legal Officer | Option exercise | 5K | $34.70 | $156K | 16K |
| 2026-09-18 | MIGNONE ROBERTO | Director | Sell | 368K | $39.06 | $14.4M | 0 |
| 2026-08-21 | Weiss Amir | Chief Accounting Officer | Sell | 3K | $37.63 | $94K | 13K |
| 2026-08-21 | Weiss Amir | Chief Accounting Officer | Option exercise | 3K | $19.61 | $49K | 16K |
| 2026-08-21 | Weiss Amir | Chief Accounting Officer | Sell | 7K | $37.61 | $261K | 13K |
| 2026-08-21 | Satchi-Fainaro Ronit | Director | Sell | 415 | $37.25 | $15K | 112K |
| 2026-08-17 | Lippman Evan | EVP, Business Development | Sell | 19K | $36.57 | $680K | 26K |
| 2026-08-05 | Zaks Tal Zvi | Director | Sell | 17 | $34.87 | $593 | 73K |
| 2026-08-03 | Hughes Eric A | See "Remarks" | Sell | 26K | $34.88 | $892K | 135K |
| 2026-08-03 | Hughes Eric A | See "Remarks" | Option exercise | 53K | price not stated in the filing | not stated | 160K |
| 2026-08-03 | Jover Placid | See "Remarks" | Sell | 13K | $34.88 | $447K | 7K |
| 2026-08-03 | Jover Placid | See "Remarks" | Option exercise | 13K | price not stated in the filing | not stated | 20K |
| 2026-06-18 | Shields Matthew | EVP, Global Operations | Sell | 10K | $32.19 | $322K | 0 |
| 2026-06-11 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 107K | $34.10 | $3.6M | 66K |
| 2026-06-05 | Francis Richard D | President and CEO | Option exercise | 13K | price not stated in the filing | not stated | 1.2M |
| 2026-06-05 | Francis Richard D | President and CEO | Sell | 6K | $34.35 | $211K | 1.2M |
| 2026-06-05 | MIGNONE ROBERTO | Director | Option exercise | 14K | price not stated in the filing | not stated | 120K |
| 2026-06-05 | Zaks Tal Zvi | Director | Option exercise | 14K | price not stated in the filing | not stated | 73K |
| 2026-06-05 | Satchi-Fainaro Ronit | Director | Option exercise | 14K | price not stated in the filing | not stated | 112K |
| 2026-06-05 | Nisen Perry | Director | Option exercise | 14K | price not stated in the filing | not stated | 120K |
| 2026-06-05 | LIEBERMAN GERALD M | Director | Option exercise | 14K | price not stated in the filing | not stated | 130K |
| 2026-06-05 | Elstein Amir | Director | Option exercise | 14K | price not stated in the filing | not stated | 2.1M |
| 2026-06-05 | Crane Rosemary A | Director | Option exercise | 14K | price not stated in the filing | not stated | 128K |
| 2026-06-05 | Lichtenstein Chen | Director | Option exercise | 14K | price not stated in the filing | not stated | 19K |
| 2026-06-05 | BARER SOL J | Director | Option exercise | 22K | price not stated in the filing | not stated | 448K |
| 2026-06-03 | Shields Matthew | EVP, Global Operations | Sell | 16K | $32.87 | $532K | 10K |
| 2026-06-03 | Shields Matthew | EVP, Global Operations | Option exercise | 16K | price not stated in the filing | not stated | 26K |
| 2026-05-14 | Lippman Evan | EVP, Business Development | Sell | 36K | $35.58 | $1.3M | 44K |
| 2026-05-14 | Lippman Evan | EVP, Business Development | Option exercise | 12K | price not stated in the filing | not stated | 12K |
| 2026-05-14 | Lippman Evan | EVP, Business Development | Sell | 6K | $35.58 | $204K | 6K |
| 2026-05-14 | Lippman Evan | EVP, Business Development | Option exercise | 74K | price not stated in the filing | not stated | 80K |
| 2026-05-14 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | Sell | 153K | $35.61 | $5.5M | 172K |
| 2026-05-06 | Weiss Amir | Chief Accounting Officer | Sell | 11K | $36.00 | $384K | 20K |
| 2026-05-05 | Daniell Richard | EVP, Europe Commercial | Sell | 30K | $35.40 | $1.1M | 56K |
| 2026-05-01 | Sabag Mark | See "Remarks" | Sell | 144K | $34.99 | $5.0M | 81K |
| 2026-04-30 | Fox Christine | EVP, U.S. Commercial | Sell | 21K | $35.31 | $751K | 64K |
| 2026-03-17 | Sabag Mark | See "Remarks" | Sell | 62K | $30.14 | $1.9M | 225K |
| 2026-03-05 | Shields Matthew | EVP, Global Operations | Option exercise | 17K | price not stated in the filing | not stated | 27K |
| 2026-03-05 | Shields Matthew | EVP, Global Operations | Sell | 17K | $31.67 | $548K | 10K |
| 2026-03-05 | Savage Brian | Interim Chief Legal Officer | Sell | 1K | $31.67 | $36K | 11K |
| 2026-03-05 | Savage Brian | Interim Chief Legal Officer | Option exercise | 4K | price not stated in the filing | not stated | 12K |
| 2026-03-05 | Jover Placid | "See ""Remarks""" | Option exercise | 14K | price not stated in the filing | not stated | 21K |
| 2026-03-05 | Jover Placid | "See ""Remarks""" | Sell | 14K | $31.67 | $448K | 7K |
| 2026-03-05 | Daniell Richard | EVP, Europe Commercial | Option exercise | 17K | price not stated in the filing | not stated | 103K |
| 2026-03-05 | Daniell Richard | EVP, Europe Commercial | Sell | 17K | $31.67 | $548K | 86K |
| 2026-03-05 | Hughes Eric A | "See ""Remarks""" | Sell | 10K | $31.67 | $302K | 108K |
| 2026-03-05 | Hughes Eric A | "See ""Remarks""" | Option exercise | 20K | price not stated in the filing | not stated | 117K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON39 Form 144 notices on file for TEVA worth $113.8M at the prices reported; 5 in the last 90 days worth $16.7M. Latest: Savage Brian filed on 2026-09-21 to sell 7,028 shares ($273K) from 2026-09-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-21 | Savage BrianOfficer, CHIEF LEGAL OFFICER | 7K | $273K | 0.000% | 2026-09-18 | CITIGROUP GLOBAL MARKETS |
| 2026-09-18 | Bridger Management, LLC (1)Shareholder | 368K | $14.4M | 0.032% | 2026-09-18 | Apex Clearing Corporation |
| 2026-08-17 | Lippman EvanOfficer, EVP BUSINESS DEVELOPMENT | 19K | $680K | 0.002% | 2026-08-17 | CITIGROUP GLOBAL MARKETS |
| 2026-08-03 | Jover PlacidExecutive VP, Chief HR Officer | 13K | $447K | 0.001% | 2026-08-03 | Citigroup Global Markets, Inc |
| 2026-08-03 | Hughes Eric AExecutive VP Global R&D and Chief Med Officer | 26K | $892K | 0.002% | 2026-08-03 | Citigroup Global Markets, Inc |
| 2026-06-18 | Shields MatthewOfficer, EXECUTIVE VP TEVA GLOBAL OPERATIONS | 10K | $322K | 0.001% | 2026-06-18 | CITIGROUP GLOBAL MARKETS |
| 2026-06-11 | Kalif Eliyahu SharonOfficer, EVP CHIEF FINANCIAL OFFICER | 107K | $3.6M | 0.009% | 2026-06-11 | CITIGROUP GLOBAL MARKETS |
| 2026-06-05 | Francis Richard DOfficer, PRESIDENT AND CEO | 6K | $211K | 0.001% | 2026-06-05 | CITIGROUP GLOBAL MARKETS INC |
| 2026-06-03 | Shields MatthewOfficer, EXECUTIVE VP TEVA GLOBAL OPERATIONS | 16K | $532K | 0.001% | 2026-06-03 | CITIGROUP GLOBAL MARKETS |
| 2026-05-14 | Lippman EvanOfficer, EXECUTIVE VP BUSINESS DEVELOPMENT | 42K | $1.5M | 0.004% | 2026-05-14 | CITIGROUP GLOBAL MARKETS |
| 2026-05-14 | Kalif Eliyahu SharonOfficer, EVP CHIEF FINANCIAL OFFICER | 153K | $5.5M | 0.013% | 2026-05-14 | CITIGROUP GLOBAL MARKETS |
| 2026-05-05 | Daniell RichardOfficer, EXECUTIVE VP EUROPEAN COMMERCIAL | 30K | $1.1M | 0.003% | 2026-05-05 | CITIGROUP GLOBAL MARKETS INC |
| 2026-05-04 | Sabag MarkOfficer, EXECUTIVE VP INTERNATIONAL MARKETS COMMERCIAL | 144K | $5.0M | 0.012% | 2026-05-01 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-17 | Sabag MarkOfficer, EXECUTIVE VP INTERNATIONAL MARKETS COMMERCIAL | 62K | $1.9M | 0.005% | 2026-03-17 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-05 | Shields MatthewOfficer, EXECUTIVE VP TEVA GLOBAL OPERATIONS | 17K | $548K | 0.002% | 2026-03-05 | CITIGROUP GLOBAL MARKETS |
| 2026-03-05 | Savage BrianOfficer, INTERIM CHIEF LEGAL OFFICER | 1K | $36K | 0.000% | 2026-03-05 | CITIGROUP GLOBAL MARKETS |
| 2026-03-05 | Jover PlacidOfficer, EXECUTIVE VP CHIEF HUMAN RESOURCES OFFICER | 14K | $448K | 0.001% | 2026-03-05 | CITIGROUP GLOBAL MARKETS |
| 2026-03-05 | Hughes Eric AOfficer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | 10K | $302K | 0.001% | 2026-03-05 | CITIGROUP GLOBAL MARKETS |
| 2026-03-05 | Francis Richard DOfficer, PRESIDENT AND CEO | 20K | $634K | 0.002% | 2026-03-05 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-05 | Fox ChristineOfficer, EVP HEAD OF US COMMERCIAL | 8K | $251K | 0.001% | 2026-03-05 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-05 | Daniell RichardOfficer, EXECUTIVE VP EUROPEAN COMMERCIAL | 17K | $548K | 0.002% | 2026-03-05 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-04 | Hughes Eric AOfficer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | 11K | $366K | 0.001% | 2026-03-04 | CITIGROUP GLOBAL MARKETS |
| 2026-03-04 | Francis Richard DOfficer, PRESIDENT AND CEO | 23K | $759K | 0.002% | 2026-03-04 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-04 | Fox ChristineOfficer, EVP HEAD OF US COMMERCIAL | 10K | $322K | 0.001% | 2026-03-04 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-04 | Daniell RichardOfficer, EXECUTIVE VP EUROPEAN COMMERCIAL | 91K | $3.0M | 0.008% | 2026-03-04 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-03 | Savage BrianOfficer, EXECUTIVE VP INTERIM CHIEF LEGAL OFFICER | 1K | $41K | 0.000% | 2026-03-03 | CITIGROUP GLOBAL MARKETS |
| 2026-03-03 | Hughes Eric AOfficer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | 81K | $2.6M | 0.007% | 2026-03-03 | CITIGROUP GLOBAL MARKETS |
| 2026-03-03 | Francis Richard DOfficer, PRESIDENT AND CEO | 443K | $14.3M | 0.039% | 2026-03-03 | CITIGROUP GLOBAL MARKETS INC |
| 2026-03-03 | Daniell RichardOfficer, EXECUTIVE VP EUROPEAN COMMERCIAL | 129K | $4.2M | 0.011% | 2026-03-03 | CITIGROUP GLOBAL MARKETS INC |
| 2026-02-26 | Kalif Eliyahu SharonOfficer, EVP CHIEF FINANCIAL OFFICER | 346K | $11.6M | 0.030% | 2026-02-26 | CITIGROUP GLOBAL MARKETS |
| 2026-02-18 | Francis Richard DOfficer, PRESIDENT AND CEO | 448K | $15.3M | 0.039% | 2026-02-17 | CITIGROUP GLOBAL MARKETS |
| 2026-02-18 | Francis Richard DOfficer, PRESIDENT AND CEO | 448K | $448K | 2.922% | 2026-02-17 | CITIGROUP GLOBAL MARKETS INC |
| 2025-12-12 | Bridger Management, LLC (1)Shareholder | 150K | $4.5M | 0.013% | 2025-12-12 | Piper Sandler & Co. |
| 2025-12-09 | Sabag MarkOfficer, EXECUTIVE VP INTERNATIONAL MARKETS COMMERCIAL | 217K | $6.2M | 0.019% | 2025-12-09 | CITIGROUP GLOBAL MARKETS INC |
| 2025-12-09 | Daniell RichardOfficer, EXECUTIVE VP EUROPEAN COMMERCIAL | 115K | $3.3M | 0.010% | 2025-12-09 | CITIGROUP GLOBAL MARKETS INC |
| 2025-11-26 | Bridger Management, LLC (1)Shareholder | 50K | $1.2M | 0.004% | 2025-11-26 | Piper Sandler & Co. |
| 2025-11-20 | Fox ChristineOfficer, EVP HEAD OF US COMMERCIAL | 28K | $700K | 0.002% | 2025-11-20 | CITIGROUP GLOBAL MARKETS INC |
| 2025-11-14 | Fox ChristineOfficer, EVP HEAD OF US COMMERCIAL | 30K | $753K | 0.003% | 2025-11-14 | CITIGROUP GLOBAL MARKETS INC |
| 2025-11-06 | Bridger Management, LLC (1)Shareholder | 200K | $4.9M | 0.017% | 2025-11-06 | Piper Sandler & Co. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of TEVA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Harel Insurance Investments & Financial Services Ltd at 6.3% of the class (72,325,555 shares), filed 2026-02-09 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-02-17 | 13G | Migdal Insurance & Financial Holdings Ltdcorporation | 61.7M | 5.4% | 2025-12-31 |
| 2026-02-09 | 13G/Ano. 1 | Harel Insurance Investments & Financial Services Ltdcorporation | 72.3M | 6.3% | 2025-12-31 |
| 2025-11-05 | 13G/Ano. 3 | FMR LLCparent holding company | 24.6M | 2.1% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 3 | Abigail P. Johnsonindividual | 24.6M | 2.1% | 2025-09-30 |
13F holders
Tracked managers holding TEVA at their latest 13F. JSON10 of the 30 tracked managers held TEVA at their latest 13F, $332.9M in total at quarter-end prices. Millennium Management is the largest at $110.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 3.3M | $110.6M | 0.04% | +1.4M |
| Greenlight Capital (DME Capital) | 2026-06-30 | 2.9M | $97.8M | 2.50% | -25K |
| Bridgewater Associates | 2026-06-30 | 1.3M | $44.9M | 0.18% | +198K |
| Point72 Asset Management | 2026-06-30 | 1.1M | $35.9M | 0.04% | -71K |
| Duquesne Family Office | 2026-06-30 | 625K | $21.2M | 0.41% | -1.8M |
| Two Sigma Investments | 2026-06-30 | 231K | $7.8M | 0.01% | -136K |
| D. E. Shaw & Co. | 2026-06-30 | 181K | $6.1M | 0.00% | +41K |
| AQR Capital Management | 2026-06-30 | 108K | $3.6M | 0.00% | +33K |
| Citadel Advisors | 2026-06-30 | 73K | $2.5M | 0.00% | new |
| ARK Investment Management | 2026-06-30 | 69K | $2.3M | 0.02% | +374 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Teva Pharmaceutical Industries reported revenue of $4.14B, down 0.8% from the same quarter a year earlier, and net loss of $576.0M (-0.49 diluted EPS). In FY 2025 it generated $1.65B of operating cash flow. As of 2026-06-30, cash was $3.65B against $4.50B of debt.
- Cash
- $3.65B
- Debt
- $4.50B
- Equity
- $7.75B
- Total assets
- $39.86B
- Shares outstanding
- 1,165,296,084
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $4.14B | -$576.0M | -13.9% | -0.49 |
| Q1 FY 2026 | 2026-03-31 | $3.98B | $369.0M | 9.3% | 0.31 |
| Q4 FY 2025 | 2025-12-31 | $1.50B | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $4.48B | $433.0M | 9.7% | 0.37 |
| Q2 FY 2025 | 2025-06-30 | $4.18B | $282.0M | 6.8% | 0.24 |
| Q1 FY 2025 | 2025-03-31 | $3.89B | $214.0M | 5.5% | 0.18 |
| Q4 FY 2024derived | 2024-12-31 | $4.23B | -$217.0M | -5.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $4.33B | -$437.0M | -10.1% | -0.39 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $17.26B | $1.41B | $1.65B | $501.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $16.54B | -$1.64B | $1.25B | $498.0M | n/a | n/a |
| FY 2023 | 2023-12-31 | $15.85B | -$559.0M | $1.37B | $526.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $14.93B | -$2.45B | $1.59B | $548.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $15.88B | $417.0M | $798.0M | $562.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-06-30 from the cover page.
What this page is
Teva Pharmaceutical Industries in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Teva Pharmaceutical Industries (TEVA), SEC CIK 818686, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-21.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-02-17.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 818686Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of TEVA is sold short?
29,848,805 shares were held short at the 2026-09-30 settlement, 5.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TEVA's daily short volume?
On 2026-10-09, 2,818,739 of the 7,778,846 TEVA shares reported to FINRA were sold short, 36.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TEVA have fails to deliver?
The SEC's latest file shows 12,764 TEVA shares failed to deliver at settlement 2026-09-14. Fails are reported per settlement date and published twice a month with a lag.
Are TEVA insiders buying or selling?
Insiders at TEVA reported 11 open-market sells worth $17.0M in the last 90 days and no open-market buys. Latest filing: Savage Brian (Interim Chief Legal Officer) on 2026-09-18.
Have TEVA insiders filed to sell?
39 Form 144 notices on file for TEVA worth $113.8M at the prices reported; 5 in the last 90 days worth $16.7M. Latest: Savage Brian filed on 2026-09-21 to sell 7,028 shares ($273K) from 2026-09-18.
Who owns 5% or more of TEVA?
2 holders report 5% or more of TEVA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Harel Insurance Investments & Financial Services Ltd at 6.3% of the class (72,325,555 shares), filed 2026-02-09 for an event on 2025-12-31.
What did TEVA report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Teva Pharmaceutical Industries reported revenue of $4.14B, down 0.8% from the same quarter a year earlier, and net loss of $576.0M (-0.49 diluted EPS). In FY 2025 it generated $1.65B of operating cash flow. As of 2026-06-30, cash was $3.65B against $4.50B of debt.
Which tracked 13F managers own TEVA?
10 of the 30 tracked 13F managers held TEVA shares at their latest filing, $332.9M in all. The largest: Izzy Englander's Millennium Management (3.3M shares, $110.6M), David Einhorn's Greenlight Capital (DME Capital) (2.9M shares, $97.8M), Ray Dalio's Bridgewater Associates (1.3M shares, $44.9M), Steve Cohen's Point72 Asset Management (1.1M shares, $35.9M), Stanley Druckenmiller's Duquesne Family Office (625K shares, $21.2M), Two Sigma Investments (231K shares, $7.8M). The table above lists all 10.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.